Future Promising For JNJ Investors, Amid Dark Times Of Ebola Outbreak
- JNJ is racing to find a vaccine that will stem the Ebola epidemic.
- As JNJ's international sales were reported as slightly lower in Q3, successful commercializing of this treatment could offer significant increases for JNJ shareholders.
- WHO recently announced the number of Ebola cases has reached 10,000 and shows no signs of slowing; the CDC estimates this figure could reach 550,000 by January.
- With a strong foundation, and free cash flow of ~$14 billion in 2013, JNJ is well poised and flexible to make this new investment.